Mice with Hoxa10 switched off and neighboring genes partly disabled had 90% fewer labeled skeletal stem cells and their descendants after 15 months, and their fractures healed less well
Mice with Hoxa10 switched off and neighboring genes partly disabled had 90% fewer labeled skeletal stem cells and their descendants after 15 months, and their fractures healed less well
On November 4, Science Advances published a study by orthopedic trauma surgeon Philipp Leucht's group at New York University. The researchers labeled cells expressing Hoxa10 in mice, switched off that gene in those cells, and partly disabled neighboring genes.
Bone heals through the activity of stem cells in the periosteum and bone marrow. A stem cell either divides to replenish the pool or matures, for example into an osteoblast, a cell that builds bone. A mature cell generally does not revert to a stem cell: maturation depletes the pool, while division replenishes it. In a 2019 study, Leucht's laboratory examined pelvic bone from 36 patients with fractures. Older patients had fewer stem cells in their samples, and lower stem cell numbers were associated with longer fracture healing times.
Hoxa10 belongs to the Hox family. These genes establish the body's spatial organization in the embryo, giving cells information about their location. In a 2023 study, the same group found that Hox gene activity declines with age in periosteal stem cells, and that adding Hoxa10 at the fracture site partially restored healing in 13-month-old mice.
Hoxa10 is the most active Hox gene in the tibial periosteum, with particularly high expression in the least mature cells. Other Hox genes can compensate for the loss of one family member, so the researchers also partly disabled the remaining genes in the HoxA cluster. These genes retained one functional copy out of two, while Hoxa10 was switched off completely. To test whether stem cells need Hoxa10 throughout life, the researchers gave mice tamoxifen on the sixth day after birth to activate a heritable label and switch off the genes. After 15 months, the mutant mice had 90% fewer labeled cells and their descendants than controls.
After a fracture, mutant stem cells proliferated less, and at 14 days the callus, a temporary bridge of tissue between the bone fragments, contained 33% less bone. An experiment that used a toxin to kill Hoxa10-expressing cells produced the same reduction. The authors concluded that these cells contribute little to healing without Hox genes. To test whether the stem cell pool was replenished, the researchers fractured the bone repeatedly. In the mutants, the pool recovered less well after the second fracture, and the bones failed to unite more often after the third.
Mutant cells matured prematurely. Based on gene activity, 55% of their cells in the callus at 14 days were classified as mature osteoblasts, compared with 22% in controls. In a Petri dish, mutant cells deposited more mineral, fat, and cartilage, while less bone formed in the animals. The authors suggest that this difference arose because the starting cell numbers were equalized in culture, whereas the stem cell pool in the animals was depleted prematurely.
In immature cells, Hoxa10 supports the production of collagen III, a protein in the early bone scaffold. Mutants had less collagen III, and their collagen fibers were less well organized. Studies in laboratory cell lines had suggested that Hoxa10 promotes osteoblast maturation. In cells taken from mouse bones, however, its activity declines as the cells mature.
To prevent Hox genes from compensating for one another, the researchers simultaneously suppressed three of them, HOXA10, HOXA11, and HOXC10, in cells from patient bone biopsies. The proportion of stem cells fell by 84%, and the number of dying cells increased by 50%. The authors propose that declining Hox gene activity is one of the immediate causes of age-related stem cell dysfunction.
“Most bone studies ask how stem cells become bone,” Leucht says in a press release about Hoxa10. “We asked how they remain available as a reserve of stem cells in the first place. Without the gene we are studying, bone uses up its reserves too early, which is what we see in aging bone.”